ZYNE - Zynerba Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

29.85M

Cash

35.97M

Avg Qtr Burn

-7.91M

Short % of Float

1.19%

Insider Ownership

6.07%

Institutional Own.

12.13%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Zygel (ZYN002 CBD Gel) Details Genetic disorder, Rare genetic disease, Fragile X syndrome	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zygel (ZYN002 CBD Gel) Details Genetic disorder, Rare genetic disease, Deletion Syndrome	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zygel (ZYN002 CBD Gel) Details Epilepsy	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zygel (ZYN002 CBD Gel) Details Autism spectrum disorders	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.